INTRODUCTION: Molecular imaging of human epidermal growth factor receptor type 2 (HER2)-expression in malignant tumors provides potentially important information for patient management. Affibody molecules have shown to be suitable tracers for imaging applications using single photon emission computed tomography or positron emission tomography. Results from an earlier evaluation of the application of site-specific (99m)Tc-labeling of the Affibody molecule, Z(HER2:2395)-C, were favorable. METHODS: As a preparation for clinical application of this tracer, we have developed and evaluated a robust single-vial freeze-dried kit, allowing labeling of the Affibody molecule, Z(HER2:2395)-C, with (99m)Tc. RESULTS: The composition of the kit [containing glucoheptonate, EDTA and tin(II)-chloride], as well as the protein amount and the pertechnetate volume were optimized for a high labeling yield (>90%) and minimal presence of reduced hydrolyzed technetium colloids (<1%). The specificity to HER2 receptors, the binding competence and the stability in phosphate-buffered saline and murine serum were verified in vitro. The shelf-life was also evaluated in vitro, showing no reduction in labeling yield or binding capacity to HER2-expressing cells after over 400 days of storage of the single-vial freeze-dried kit. CONCLUSIONS: Z(HER2:2395)-C labeled with (99m)Tc using the lyophilized kit was stable and resulted in a favorable biodistribution in an in vivo evaluation in normal Naval Medical Research Institute mice. Copyright 2010 Elsevier Inc. All rights reserved.
INTRODUCTION: Molecular imaging of human epidermal growth factor receptor type 2 (HER2)-expression in malignant tumors provides potentially important information for patient management. Affibody molecules have shown to be suitable tracers for imaging applications using single photon emission computed tomography or positron emission tomography. Results from an earlier evaluation of the application of site-specific (99m)Tc-labeling of the Affibody molecule, Z(HER2:2395)-C, were favorable. METHODS: As a preparation for clinical application of this tracer, we have developed and evaluated a robust single-vial freeze-dried kit, allowing labeling of the Affibody molecule, Z(HER2:2395)-C, with (99m)Tc. RESULTS: The composition of the kit [containing glucoheptonate, EDTA and tin(II)-chloride], as well as the protein amount and the pertechnetate volume were optimized for a high labeling yield (>90%) and minimal presence of reduced hydrolyzed technetium colloids (<1%). The specificity to HER2 receptors, the binding competence and the stability in phosphate-buffered saline and murine serum were verified in vitro. The shelf-life was also evaluated in vitro, showing no reduction in labeling yield or binding capacity to HER2-expressing cells after over 400 days of storage of the single-vial freeze-dried kit. CONCLUSIONS: Z(HER2:2395)-C labeled with (99m)Tc using the lyophilized kit was stable and resulted in a favorable biodistribution in an in vivo evaluation in normal Naval Medical Research Institute mice. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Hanna Lindberg; Camilla Hofström; Mohamed Altai; Hadis Honorvar; Helena Wållberg; Anna Orlova; Stefan Ståhl; Torbjörn Gräslund; Vladimir Tolmachev Journal: Tumour Biol Date: 2012-01-17
Authors: Ken G Andersson; Maryam Oroujeni; Javad Garousi; Bogdan Mitran; Stefan Ståhl; Anna Orlova; John Löfblom; Vladimir Tolmachev Journal: Int J Oncol Date: 2016-10-05 Impact factor: 5.650
Authors: Ayman Abouzayed; Sara S Rinne; Hamideh Sabahnoo; Jens Sörensen; Vladimir Chernov; Vladimir Tolmachev; Anna Orlova Journal: Pharmaceutics Date: 2021-01-30 Impact factor: 6.321
Authors: Maryam Oroujeni; Sara S Rinne; Anzhelika Vorobyeva; Annika Loftenius; Joachim Feldwisch; Per Jonasson; Vladimir Chernov; Anna Orlova; Fredrik Y Frejd; Vladimir Tolmachev Journal: Int J Mol Sci Date: 2021-03-09 Impact factor: 5.923